InMed Pharmaceuticals Price Cash Flow Ratio Over Time
| INM Stock | USD 2.65 0.20 7.02% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out InMed Pharmaceuticals Performance and InMed Pharmaceuticals Correlation. InMed |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.26) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets | Return On Equity |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Price Cash Flow Ratio Analysis
Compare InMed Pharmaceuticals and related stocks such as Quoin Pharmaceuticals, Allarity Therapeutics, and Kiromic Biopharma Price Cash Flow Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QNRX | (9.9467) | (9.9467) | (9.9467) | (9.9467) | (9.9467) | (9.9467) | (3.7375) | (7.8715) | (2.0672) | (3.6345) | (19.3863) | (1.2607) | (0.8115) | (0.5625) | (0.51) | (0.53) |
| ALLR | (3.3897) | (3.3897) | (3.3897) | (3.3897) | (3.3897) | (3.3897) | (3.3897) | (3.3897) | (3.3897) | (3.3897) | (4.7276) | (4.3835) | (0.1664) | (51.6 K) | (59.4 K) | (56.4 K) |
| VRAX | (278) | (278) | (278) | (278) | (278) | (278) | (278) | (278) | (278) | (278) | (351) | (256) | (1.7685) | (0.2361) | (0.21) | (0.22) |
| BDRX | (0.0918) | (0.0918) | (0.0918) | (0.0918) | (0.0918) | (0.0918) | (0.0918) | (0.0918) | (0.0918) | (0.0918) | (0.0788) | (0.13) | (0.0285) | (6.0E-4) | (5.0E-4) | (6.0E-4) |
| ICU | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (4.3136) | (0.9321) | (1.07) | (1.13) |
| ZVSA | (31.3763) | (31.3763) | (31.3763) | (31.3763) | (31.3763) | (31.3763) | (31.3763) | (31.3763) | (31.3763) | (31.3763) | (31.3763) | (31.5848) | (9.5302) | (0.1006) | (0.0906) | (0.0951) |
| SONN | (36.1217) | (21.5 M) | (5 M) | (220) | (422) | (67.8869) | (286) | (146) | (65.346) | (24.7823) | (5.2716) | (1.8433) | (1.115) | (0.5093) | (65.346) | (68.61) |
| REVB | (6.8 K) | (6.8 K) | (6.8 K) | (6.8 K) | (6.8 K) | (6.8 K) | (6.8 K) | (6.8 K) | (6.8 K) | (6.8 K) | (6.8 K) | (145) | (5.1147) | (7.5206) | (6.77) | (7.11) |
| PALI | (28.6188) | (519) | (673) | (1.8 K) | (1.8 K) | (450) | (228) | (168) | (66.727) | (23.1354) | (46.0825) | (0.6899) | (0.3426) | (0.3625) | (0.33) | (0.34) |
| DRUG | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (190) | (11.0837) | (1.5455) | (1.1383) | (1.1383) | (1.02) | (1.08) |
| TNXP | (1.1 M) | (59.7 K) | (131) | (131) | (131) | (131) | (131) | (131) | (131) | (131) | (131) | (173) | (14.5138) | (6.732) | (6.06) | (6.36) |
| IMMX | (15.6782) | (15.6782) | (15.6782) | (15.6782) | (15.6782) | (15.6782) | (15.6782) | (15.6782) | (15.6782) | (15.6782) | (70.4969) | (29.6319) | (4.0892) | (10.5527) | (9.5) | (9.97) |
| PHIO | 0.0 | 0.0 | (2.3446) | (5.393) | (4.5282) | (3.4078) | (0.6206) | (1.3173) | (0.3084) | (0.5008) | (1.4005) | (1.0809) | (0.4179) | (0.147) | (0.13) | (0.14) |
| ATNF | (22.1571) | (22.1571) | (22.1571) | (22.1571) | (22.1571) | (22.1571) | (22.1571) | (22.1571) | (3.7814) | (5.147) | (12.5925) | (6.2734) | (0.5311) | (0.1409) | (0.13) | (0.13) |
| NBY | (190) | (385) | (177) | (9.4092) | (9.4092) | (9.4092) | (9.4092) | (9.4092) | (1.9722) | (1.6086) | (5.1785) | (1.5878) | (0.3077) | (0.2081) | (0.19) | (0.2) |
| GOVX | (96.1236) | (369) | (45.8817) | (66.0977) | (49.7792) | (41.404) | (57.5549) | (66.3376) | (72.5902) | (80.0921) | (46.8164) | (12.3178) | (1.2612) | (0.5468) | (0.63) | (0.66) |
InMed Pharmaceuticals and related stocks such as Quoin Pharmaceuticals, Allarity Therapeutics, and Kiromic Biopharma Price Cash Flow Ratio description
My Equities
My Current Equities and Potential Positions
| InMed Pharmaceuticals | INM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | British Columbia; Canada |
| Exchange | NASDAQ Exchange |
USD 2.65
Check out InMed Pharmaceuticals Performance and InMed Pharmaceuticals Correlation. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
InMed Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.